Aldesleukin (Recombinant interleukin-2). A review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma (vol 7, pg 285, 1997)

被引：0
|
作者：
Jeal, W
Goa, KL
机构：
来源：
BIODRUGS | 1997年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：192 / 192
页数：1
相关论文
共 50 条
  • [11] RECOMBINANT INTERLEUKIN-2 FOR METASTATIC RENAL-CELL CARCINOMA IN HEMODIALYSIS-PATIENTS
    BUTER, J
    JANSSEN, RAJ
    MULDER, NH
    DEJONG, PE
    DELEIJ, L
    SLEIJFER, DT
    EUROPEAN JOURNAL OF CANCER, 1992, 28A (10) : 1770 - 1771
  • [12] Review of inhaled recombinant interleukin-2 (rIL-2) in patients with renal cell carcinoma with pulmonary metastases.
    Michelson, G
    Esteban, E
    Garcia-Giron, C
    Jimenez-Lacave, A
    Canelas, A
    Maroto, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 441S - 441S
  • [13] Antitumor Efficacy of Recombinant Human Interleukin-2 Combined with Sorafenib Against Mouse Renal Cell Carcinoma
    Iguchi, Motofumi
    Matsumoto, Mitsunobu
    Hojo, Kanji
    Wada, Toru
    Matsuo, Yoshiyuki
    Arimura, Akinori
    Abe, Kenji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (05) : 303 - 309
  • [14] IMMUNOLOGICAL STUDY OF HUMAN RECOMBINANT INTERLEUKIN-2 IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA
    MARUMO, K
    MURAKI, J
    UENO, M
    DEGUCHI, N
    BABA, S
    TAZAKI, H
    JOURNAL OF UROLOGY, 1987, 137 (04): : A146 - A146
  • [15] RECOMBINANT INTERFERON-ALPHA-2A AND INTERLEUKIN-2 IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
    JURINCICWINKLER, C
    HORLBECK, R
    KLIPPEL, KF
    WIENER KLINISCHE WOCHENSCHRIFT, 1993, 105 (10) : 271 - 276
  • [16] Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma (vol 49, pg 63, 2003)
    Boehm, M.
    Ittenson, A.
    Klatte, T.
    Schierbaum, K. F.
    Roehl, F. W.
    Ansorge, S.
    Allhoff, E. P.
    FOLIA BIOLOGICA, 2012, 58 (02) : 87 - 87
  • [17] Subcutaneous interleukin-2 and interferon in the treatment of patients with metastatic renal cell carcinoma -: Less efficacy compared with intravenous interleukin-2 and interferon α
    Ravaud, A
    Delva, R
    Gomez, F
    Chevreau, C
    Douillard, JY
    Peny, J
    Coudert, B
    Négrier, S
    CANCER, 2002, 95 (11) : 2324 - 2330
  • [18] Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application
    Kirchner, GI
    Franzke, A
    Buer, J
    Beil, W
    Probst-Kepper, M
    Wittke, F
    Övermann, K
    Lassmann, S
    Hoffmann, R
    Kirchner, H
    Ganser, A
    Atzpodien, J
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (01) : 5 - 10
  • [19] PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA TREATED WITH RECOMBINANT INTERLEUKIN-2
    PALMER, PA
    VINKE, J
    PHILIP, T
    NEGRIER, S
    ATZOPODIEN, J
    KIRCHNER, H
    OSKAM, R
    FRANKS, CR
    ANNALS OF ONCOLOGY, 1992, 3 (06) : 475 - 480
  • [20] Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2:: an outcome study
    Huland, E
    Burger, A
    Fleischer, J
    Fornara, P
    Hatzmann, E
    Heidenreich, A
    Heinzer, H
    Heynemann, H
    Hoffmann, L
    Hofmann, R
    Huland, H
    Kämpfer, I
    Kindler, M
    Kirchner, H
    Mehlhorn, G
    Moniak, TH
    Rebmann, U
    Roigas, J
    Schneider, TH
    Schnorr, D
    Schmitz, HJ
    Wenisch, R
    Varga, Z
    Vinke, J
    FOLIA BIOLOGICA, 2003, 49 (05) : 183 - 190
12345